These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 17617203)

  • 21. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening.
    Park DI; Ryu S; Kim YH; Lee SH; Lee CK; Eun CS; Han DS
    Am J Gastroenterol; 2010 Sep; 105(9):2017-25. PubMed ID: 20502450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test.
    Levi Z; Hazazi R; Rozen P; Vilkin A; Waked A; Niv Y
    Aliment Pharmacol Ther; 2006 May; 23(9):1359-64. PubMed ID: 16629942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
    Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
    Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can patients at high risk for significant colorectal neoplasms and having normal quantitative faecal occult blood test postpone elective colonoscopy?
    Hazazi R; Rozen P; Leshno M; Levi Z; Samuel Z; Waked A; Vilkin A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2010 Feb; 31(4):523-33. PubMed ID: 19925498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report.
    Young GP; St John DJ; Winawer SJ; Rozen P;
    Am J Gastroenterol; 2002 Oct; 97(10):2499-507. PubMed ID: 12385430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the sensitivity of an immunochemical fecal occult blood test for colorectal neoplasia.
    Yoshinaga M; Motomura S; Takeda H; Yanagisawa Z; Ikeda K
    Am J Gastroenterol; 1995 Jul; 90(7):1076-9. PubMed ID: 7611200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer.
    Faivre J; Dancourt V; Denis B; Dorval E; Piette C; Perrin P; Bidan JM; Jard C; Jung S; Levillain R; Viguier J; Bretagne JF
    Eur J Cancer; 2012 Nov; 48(16):2969-76. PubMed ID: 22572481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective study of a new immunochemical fecal occult blood test in Korean patients referred for colonoscopy.
    Woo HY; Mok RS; Park YN; Park DI; Sung IK; Sohn CI; Park H
    Clin Biochem; 2005 Apr; 38(4):395-9. PubMed ID: 15766742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnetic resonance colonography for the detection of colorectal neoplasia in asymptomatic adults.
    Graser A; Melzer A; Lindner E; Nagel D; Herrmann K; Stieber P; Schirra J; Mansmann U; Reiser MF; Göke B; Kolligs FT
    Gastroenterology; 2013 Apr; 144(4):743-750.e2. PubMed ID: 23415805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of three FOBT protocols for colorectal cancer screening in Chinese--a multicenter study].
    Li SR; Wang HH; Hu JC; Li N; Liu YL; Wu ZT; Zheng Y; Wang HH; Wu K; Ye H
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(10):697-700. PubMed ID: 15932737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small adenomas detected during fecal occult blood test screening for colorectal cancer. The impact of serendipity.
    Ransohoff DF; Lang CA
    JAMA; 1990 Jul; 264(1):76-8. PubMed ID: 2192093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study.
    Hoepffner N; Shastri YM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein J
    Aliment Pharmacol Ther; 2006 Jan; 23(1):145-54. PubMed ID: 16393292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic value of immunochemical fecal occult blood test for small colorectal neoplasms.
    Abdul Fattah AS; Nakama H; Zhang B; Uehara Y; Kamijo N; Fujimori K
    Eur J Med Res; 1997 May; 2(5):227-30. PubMed ID: 9153349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Screening for colorectal cancer in high-risk and intermediate-risk subject: what's the best tool?].
    Trevisani L; Cifalà V; Sartori S; Tombesi P; Matarese V; Pezzoli A; Abbasciano V
    Recenti Prog Med; 2009 Feb; 100(2):68-72. PubMed ID: 19350797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population.
    Graser A; Stieber P; Nagel D; Schäfer C; Horst D; Becker CR; Nikolaou K; Lottes A; Geisbüsch S; Kramer H; Wagner AC; Diepolder H; Schirra J; Roth HJ; Seidel D; Göke B; Reiser MF; Kolligs FT
    Gut; 2009 Feb; 58(2):241-8. PubMed ID: 18852257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fecal occult blood testing when colonoscopy capacity is limited.
    Wilschut JA; Habbema JD; van Leerdam ME; Hol L; Lansdorp-Vogelaar I; Kuipers EJ; van Ballegooijen M
    J Natl Cancer Inst; 2011 Dec; 103(23):1741-51. PubMed ID: 22076285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal occult blood testing for colorectal cancer screening: use the finger.
    Burke CA; Tadikonda L; Machicao V
    Am J Gastroenterol; 2001 Nov; 96(11):3175-7. PubMed ID: 11721767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of conventional guaiac to four immunochemical methods for fecal occult blood testing: implications for clinical practice in hospital and outpatient settings.
    Tannous B; Lee-Lewandrowski E; Sharples C; Brugge W; Bigatello L; Thompson T; Benzer T; Lewandrowski K
    Clin Chim Acta; 2009 Feb; 400(1-2):120-2. PubMed ID: 19000907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.